cjc 1395 ipamorelin CJC-1295 + CJC-1295/Ipamorelin – C2 Peptides
Description
Maintenance phase (weeks 512): 22.5 mg SC, once weekly
CDK4/6 inhibitor can dually inhibit CDK4/6 and ER signaling
The harsh GI environment promotes enzymatic degradation and poor absorption, necessitating subcutaneous injections, which compromise patient adherence
doi: 10.1186/cc10220 128 LiYMLiYYanLWangHWuXJTangJTet al
